Emendo Biotherapeutics
DNA Correction and Genome-editing Platforms
Company Overview
Snapshot
Founded in May 2015 by Lior Izhar, Emendo Biotherapeutics operates with 11–50 employees. The company raised $73,000,000 across two funding rounds from two investors before being acquired by AnGes in December 2020.
Business overview
Emendo Biotherapeutics develops advanced gene-editing tools designed to address genetic disorders by repairing and eliminating genetic mutations in living cells. Its technology focuses on recombination-based solutions that are highly specific and aim for zero off-target effects. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and biotechnology industries with its gene-editing solutions.
Strategic signal
In December 2023, AnGes initiated layoffs impacting 110 EmendoBio employees, three years after its $250 million acquisition. This signals a significant operational restructuring within the acquired entity, indicating a potential shift in strategic priorities or integration challenges post-acquisition for the parent company.
Log in to access full profile ›Company Intelligence Q&A
- When was Emendo Biotherapeutics acquired?
- Emendo Biotherapeutics was acquired by AnGes in December 2020.
- What was a key development regarding Emendo Biotherapeutics' workforce in late 2023?
- In December 2023, AnGes initiated layoffs of 110 EmendoBio employees, three years after acquiring the company.
- What breakthrough results did Emendo Biotherapeutics announce in May 2022?
- In May 2022, Emendo Biotherapeutics announced breakthrough results with its next-generation CRISPR gene editing technologies, utilizing an allele-specific approach for ELANE-related Severe Congenital Neutropenia, as presented at the ASGCT Annual Meeting.
- Which organizations collaborated with Emendo Biotherapeutics to develop a CRISPR-based therapeutic strategy for Severe Congenital Neutropenia?
- In December 2021, Emendo Biotherapeutics and Seattle Children's Research Institute announced a collaboration to develop a CRISPR-based therapeutic strategy for Severe Congenital Neutropenia.
- Which investors participated in Emendo Biotherapeutics' funding round in January 2020?
- In January 2020, Emendo Biotherapeutics received funding from OrbiMed and Takeda Ventures.